When a 63-year-old Norwegian man agreed to a bone marrow transplant in 2021, he had one goal: treat a life-threatening blood disorder that drugs had failed to control. HIV was a separate problem — one he had managed with antiviral medication for over a decade, and expected to manage for the rest of his life.
Then his brother turned out to carry a rare genetic mutation. And everything changed.
The Virus That Hides
HIV is no longer the death sentence it once was. Modern antivirals can suppress the virus so effectively that it becomes undetectable in the bloodstream, allowing people to live relatively normal lives. But “undetectable” is not the same as “gone.” HIV burrows into reservoirs throughout the body — particularly in the gut — embedding itself in DNA where antivirals can’t reach it. Stop the medication, and the virus rebounds. For the roughly 40 million people living with HIV worldwide, treatment is for life.
A true cure requires something more radical: wiping out those hidden reservoirs entirely. Fewer than ten people in history have achieved it.
The Mutation That Blocks HIV
The story of HIV cures begins with a lucky accident in 2009, when a man receiving a stem cell transplant for blood cancer — now known as the Berlin patient — emerged from treatment with no detectable HIV. His donor’s cells happened to carry two copies of a mutation called CCR5Δ32, which blocks the molecular doorway HIV uses to enter and infect immune cells. Without that doorway, the virus simply can’t replicate.
Since then, a small handful of patients have achieved long-term remission through stem cell transplants carrying this protective mutation. The Oslo patient is the latest — and his case has a twist that makes it particularly striking.
An Unexpected Discovery on Transplant Day
The Norwegian man had been living with HIV since 2006, keeping it suppressed with medication while otherwise leading a normal life. But in 2017 he developed a severe bone marrow disorder, and after several treatments failed to hold it, a transplant became his only option. His medical team searched for a donor who was not only a good immune match but also carried two copies of CCR5Δ32 — a combination that would let them tackle both conditions simultaneously. Finding such a donor, as one of the researchers put it, is like searching for a needle in a haystack.
As his condition deteriorated, the team moved forward with his brother as donor, prioritising survival over the genetic ideal. It was only on transplant day itself that they discovered the brother carried both copies of the protective mutation. Nobody had known.
“We had no idea,” said the lead researcher. “That was amazing.”
What Happened Next
The results were remarkable. Within three months, the patient’s immune cells were clear of viral genetic material. The donor cells gradually took over, repopulating his bone marrow, his bloodstream, and eventually his gut — one of HIV’s most stubborn hiding places, and the first time a bone marrow transplant has achieved total replacement there.
Two years after stopping antiviral medication entirely, extensive testing across more than 65 million T cells — HIV’s primary targets — found no intact viral material capable of causing infection. The immune system appeared to have forgotten the virus ever existed. Antibodies faded. T cell counts normalised. Four years on, the man is, in his doctor’s words, “having a great time” — more energy than he knows what to do with.
“For all practical purposes, we are quite certain that he is cured.”
The Honest Limits
This is not a treatment that could be rolled out widely, and the researchers are clear about that. Bone marrow transplants carry a mortality risk of 10 to 20 percent within the first year. The Oslo patient himself experienced severe graft-versus-host disease — where transplanted cells attack the body — requiring intensive drug treatment to bring under control. The procedure is reserved for people who already face life-threatening conditions and have no other options.
There were also unexpected complexities. The patient had carried one copy of CCR5Δ32 himself, which should have offered some protection — yet he still contracted HIV years earlier. Scientists aren’t entirely sure why. And some analysis suggests the drugs used to treat the graft-versus-host disease may have played an additional role in eliminating the virus, adding another layer of uncertainty about what actually drove the cure.
Why It Matters Anyway
Rare cases like this one are more than medical curiosities. Each successful cure offers a window into how HIV behaves, where it hides, and what conditions are needed to eliminate it. Researchers are now working to compare cases across an international consortium, looking for the common threads — the biomarkers, the immune conditions, the genetic factors — that might eventually point toward scalable approaches.
The goal isn’t a bone marrow transplant for everyone. It’s understanding the biology well enough to engineer a cure that doesn’t require one.
As for the Oslo patient, his doctor summed it up simply: he is “perhaps no longer a patient. At least he doesn’t feel like it.”